Format

Send to

Choose Destination
Reprod Sci. 2008 Apr;15(3):321-6. doi: 10.1177/1933719108316390.

Lipoxygenase pathway receptor expression in ovarian cancer.

Author information

1
Department of Obstetrics and Gynecology, Mitchell Cancer Institute, University of South Alabama, Mobile, Alabama 36607, USA. rocconi@usouthal.edu

Abstract

OBJECTIVE:

To determine the expression of lipoxygenase (LOX) pathway receptors in ovarian cancer as a potential target for anti-LOX-based therapy.

STUDY DESIGN:

Paraffin-embedded tumor samples from epithelial ovarian cancer patients were used to construct tissue microarrays to stain for the proposed sites of inhibition of a LOX inhibitor (5-LOX, LTB4-BLT1, and LTB4-BLT2).

RESULTS:

245 samples were available for interpretation. Strong expression was demonstrated in 45%, 34%, and 6% of ovarian cancer for LTB4-BLT2, LTB4-BLT1, and 5-LOX, respectively. Expression of LTB4-BLT2 correlated with advanced stage III/IV disease (P = .05), suboptimal debulking (P = .07), and platinum resistance (P = .03). No correlation was seen with regard to disease-free survival.

CONCLUSIONS:

LOX pathway receptor expression was found in the majority of cancers evaluated. Additionally, LTB4-BLT2 expression portends worse clinical parameters for ovarian cancer. Thus, further investigation on the role of LOX pathway in ovarian cancer is warranted.

PMID:
18421027
DOI:
10.1177/1933719108316390
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center